Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 6/20 | 0.73 |
| ▸ | PTPN2 | P17706 | 4/20 | 0.73 |
| ▸ | USP2 | O75604 | 1/20 | 0.69 |
| ▸ | CES1 | P23141 | 5/20 | 0.67 |
| ▸ | CES2 | O00748 | 3/20 | 0.67 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | AKR1B10 | O60218 | 3/20 | 0.53 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 3/20 | 0.52 |
| ▸ | PSMB11 | A5LHX3 | 2/20 | 0.52 |
| ▸ | PSMA7 | O14818 | 2/20 | 0.52 |
| ▸ | PLA2G1B | P04054 | 2/20 | 0.52 |
| ▸ | PTPRC | P08575 | 2/20 | 0.52 |
| ▸ | PTPRF | P10586 | 2/20 | 0.52 |
| ▸ | F3 | P13726 | 2/20 | 0.52 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.52 |
| ▸ | ACP1 | P24666 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL974587 | 1.00 | PTPN1 (0.73) | PTPN1PTPN2USP2CES1CES2 | |
| SCHEMBL6913431 | 1.00 | PTPN1 (0.73) | PTPN1PTPN2USP2CES1CES2 | |
| SCHEMBL31593848 | 1.00 | PTPN1 (0.73) | PTPN1PTPN2USP2CES1CES2 | |
| SCHEMBL29624157 | 0.87 | PTPN1 (0.62) | PTPN1PTPN2USP2CES1CES2 | |
| SCHEMBL1649013 | 0.86 | CES2 (0.74) | PTPN1PTPN2USP2CES1CES2 | |
| SCHEMBL1649012 | 0.86 | CES2 (0.74) | PTPN1PTPN2USP2CES1CES2 | |
| SCHEMBL1050323 | 0.86 | CES2 (0.74) | PTPN1PTPN2USP2CES1CES2 | |
| SCHEMBL1721910 | 0.85 | PTPN1 (0.63) | PTPN1PTPN2USP2CES1CES2 | |
| SCHEMBL178210 | 0.85 | PTPN1 (1.00) | PTPN1PTPN2USP2CES1ALOX5 | |
| SCHEMBL178211 | 0.85 | PTPN1 (1.00) | PTPN1PTPN2USP2CES1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4374284-A | Antiulcer, antiinflammatory, and antiallergic agent comprising as the main ingredient olean-12-ene-3β, 30-diol which is devoid of side effects of glycyrrhetinic acid and a new process for preparation of olean-12-ene-3β, 30-diol | MINOPHAGEN PHARMACEUTICAL COMPANY (JP) | 1983-02-15 | — | — | US | claimed |
| JP-56139416-A | — | — | None | — | — | JP | disclosed |
| CN-119192273-A | New pentacyclic triterpene B extracted from oleanane type compound extracted from radix bupleuri, and extraction method and application thereof | 河南中医药大学 | 2024-12-27 | — | — | CN | disclosed |
| CN-118324844-A | Method for preparing oleanane compound pentacyclic triterpene A from radix bupleuri and application thereof | 河南中医药大学 | 2024-07-12 | — | — | CN | disclosed |
| CN-117886877-A | Secoisolariciresine type triterpene compound and application of pharmaceutical composition thereof in treatment of neuroinflammation | 中国医学科学院药物研究所 | 2024-04-16 | — | — | CN | disclosed |
| CN-114573656-B | Preparation method and application of polyoxy oleanane type triterpene compound sub-merino triterpene C | 河南中医药大学 | 2024-03-15 | — | — | CN | disclosed |
| CN-112370462-A | Methods and compositions for treating COPD diseases | 上海凯屹医药科技有限公司 | 2021-02-19 | — | — | CN | disclosed |
| CN-108840899-B | Pentacyclic triterpenoid compound and derivative and application thereof | 浙江大学 | 2020-11-10 | — | — | CN | disclosed |
| CN-106456657-B | Methods and compositions for treating COPD diseases | 上海凯屹医药科技有限公司 | 2020-10-16 | — | — | CN | disclosed |
| US-10786521-B2 | Methods and compositions for treatment of COPD diseases | Shanghai KE Pharmaceutical Co., Ltd (CN) | 2020-09-29 | — | — | US | disclosed |
| US-5916919-A | TRITERPENES | DALHOUSIE UNIVERSITY (CA) | 1999-06-29 | — | — | US | disclosed |
| US-5804239-A | Method and composition for food flavoring | NOUVEAU TECHNOLOGIES, INC. (US) | 1998-09-08 | — | — | US | disclosed |
| EP-0515159-B1 | Ursane derivatives, their preparation and pharmaceutical formulations thereof | IDB HOLDING SPA (IT) | 1995-11-29 | — | — | EP | disclosed |
| EP-0515159-A1 | Ursane derivatives, their preparation and pharmaceutical formulations thereof | IDB HOLDING S.p.A. (IT) | 1992-11-25 | — | — | EP | disclosed |
| US-4752606-A | OLEANOLIC ACID-ANTIULCER AGENT | 501 Noristan Limited (ZA) | 1988-06-21 | — | — | US | disclosed |
| EP-0093520-A1 | Pharmaceutical compositions and preparation thereof | NORISTAN LIMITED (ZA) | 1983-11-09 | — | — | EP | disclosed |
| US-4374284-A | Antiulcer, antiinflammatory, and antiallergic agent comprising as the main ingredient olean-12-ene-3β, 30-diol which is devoid of side effects of glycyrrhetinic acid and a new process for preparation of olean-12-ene-3β, 30-diol | MINOPHAGEN PHARMACEUTICAL COMPANY (JP) | 1983-02-15 | — | — | US | disclosed |
| US-4374284-A | Antiulcer, antiinflammatory, and antiallergic agent comprising as the main ingredient olean-12-ene-3β, 30-diol which is devoid of side effects of glycyrrhetinic acid and a new process for preparation of olean-12-ene-3β, 30-diol | MINOPHAGEN PHARMACEUTICAL COMPANY (JP) | 1983-02-15 | — | — | US | disclosed |
| US-4374284-A | Antiulcer, antiinflammatory, and antiallergic agent comprising as the main ingredient olean-12-ene-3β, 30-diol which is devoid of side effects of glycyrrhetinic acid and a new process for preparation of olean-12-ene-3β, 30-diol | MINOPHAGEN PHARMACEUTICAL COMPANY (JP) | 1983-02-15 | — | — | US | disclosed |
| JP-S56139416-A | ANTIULCER, ANTI-INFLAMMATORY AND ANTIALLERGIC AGENT, CONTAINING OLEAN-12-ENE-3BETA, 3O-DIOL AS MAIN CONSTITUENT, AND HAVING NO SIDE EFFECT OF GLYCYLRRHETINIC ACID | MINOFUAAGEN SEIYAKU HONPO:GOUSHI | 1981-10-30 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10786521-B2 | Methods and compositions for treatment of COPD diseases | MPO, MMP8, COX6C | PTPN1 2856/4885PTPN2 2502/4885USP2 974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.